Integrated Single-cell RNA Sequencing Atlas of White Matter Microglial Functional Diversity in Chronic Multiple Sclerosis

Abstract

Background: In multiple sclerosis (MS), chronic “smoldering” lesions are driven by microglial activation, which promotes demyelination and disease progression. However, microglia exhibit a functional dichotomy by performing both neurotoxic and reparative roles. Precisely modulating these functions remains a major therapeutic challenge, because non-specific approaches can inadvertently impair beneficial microglial functions. Delineating microglial subtypes in chronic MS is therefore essential for targeted therapy.

Methods: Single-cell RNA sequencing, spatial transcriptomics, deconvolution, and pseudotime trajectory mapping were used to characterize cell subtypes. Subsequent investigations encompassed functional annotation, differential gene expression profiling, cell-cell communication pathways, and transcription factor network analysis.

Results: We identified six distinct microglial subtypes with varied functions and focused on the highly disease-relevant C2 microglial subtype. This subtype simultaneously exhibited enhanced phagocytic and pro-inflammatory functions potentially associated with the fatty acid metabolic pathway. Pseudotime trajectory analysis suggested that this subtype is likely to represent a late disease stage. Cell-cell communication analysis revealed interactions between this subtype and both oligodendrocytes and T cells, as further supported by spatial transcriptomics demonstrating co-localization of the C2 microglial subtype with T cells. Finally, transcriptional regulatory network analysis identified an association between the FOSL2 regulon and both the C2 microglial subtype and chronic MS.

Conclusion: Through integrated single-cell sequencing approaches, we identified a C2 microglial subtype in chronic MS that might contribute to disease progression via pro-inflammatory functions. We propose the transcription factor FOSL2 as a promising hypothesis-generating candidate for future studies aimed at modulating microglial differentiation toward a less harmful state. Our findings provide mechanistic insights into the pathology of white matter lesions in chronic MS and suggest novel subtype-specific directions for the development of next-generation disease-modifying therapies.

Keywords

Biology and biochemistry / immunology / medicine / neurosciences

References

[1] McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and treatment of multiple sclerosis: a review. JAMA 2021; 325(8): 765-79. [PMID: 33620411 DOI: 10.1001/jama.2020.26858]

[2] Zhu X, Yue M, Zhang X, Han Y, Xia R, et al. Global disease burden of immune-mediated inflammatory diseases (IMIDs), 1990-2021. Med Res 2025; 1(2): 285-96. [DOI: 10.1002/mdr2.70018]

[3] Mansilla MJ, Presas-Rodriguez S, Teniente-Serra A, Gonzalez-Larreategui I, Quirant-Sanchez B, et al. Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy. Cell Mol Immunol 2021; 18(6): 1353-74. [PMID: 33958746 DOI: 10.1038/s41423-020-00618-z]

[4] Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, et al. Multiple sclerosis. Nat Rev Dis Primers 2018; 4(1): 43. [PMID: 30410033 DOI: 10.1038/s41572-018-0041-4]

[5] Al-Kuraishy HM, Sulaiman GM, Mohammed HA, Albukhaty S, Albuhadily AK, et al. The compelling role of brain-derived neurotrophic factor signaling in multiple sclerosis: role of BDNF activators. CNS Neurosci Ther 2024; 30(12): e70167. [PMID: 39654365 DOI: 10.1111/cns.70167]

[6] Feng R, Spieth L, Liu L, Berghoff S, Franz J, et al. Single-cell spatial transcriptomic profiling defines a pathogenic inflammatory niche in chronic active multiple sclerosis lesions. Immunity 2025; 58(12): 2989-3005. [PMID: 41167189 DOI: 10.1016/j.immuni.2025.10.003]

[7] Sun R, Jiang H. Border-associated macrophages in the central nervous system. J Neuroinflammation 2024; 21(1): 67. [PMID: 38481312 DOI: 10.1186/s12974-024-03059-x]

[8] Zhao T, Di J, Kang Y, Zhang H, Yao S, et al. TREM2 impedes recovery after spinal cord injury by regulating microglial lysosomal membrane permeabilization-mediated autophagy. Cell Prolif 2025; 58(10): e70047. [PMID: 40320759 DOI: 10.1111/cpr.70047]

[9] Hyvärinen T, Tilvis J, Giudice L, Tujula I, Nylund M, et al. Microglia from patients with multiple sclerosis display a cell-autonomous immune activation state. J Neuroinflammation 2025; 22(1): 255. [PMID: 41174786 DOI: 10.1186/s12974-025-03575-4]

[10] Vermersch P, Airas L, Berger T, Deisenhammer F, Grigoriadis N, et al. The role of microglia in multiple sclerosis: implications for treatment with Bruton’s tyrosine kinase inhibitors. Front Immunol 2025; 16: 1495529. [PMID: 40443664 DOI: 10.3389/fimmu.2025.1495529]

[11] Jia J, Zheng L, Ye L, Chen J, Shu S, et al. CD11c⁺ microglia promote white matter repair after ischemic stroke. Cell Death Dis 2023; 14(2): 156. [PMID: 36828819 DOI: 10.1038/s41419-023-05689-0]

[12] Baaklini CS, Ho MFS, Lange T, Hammond BP, Panda SP, et al. Microglia promote remyelination independent of their role in clearing myelin debris. Cell Rep 2023; 42(12): 113574. [PMID: 38100356 DOI: 10.1016/j.celrep.2023.113574]

[13] Zhao Z, Cai H, Zhao Z, Wang X, Nie W, et al. Cancer-associated fibroblast-derived GDF15 induces oxidative stress and neutrophil infiltration in head and neck squamous cell carcinoma through the PI3K/AKT/STAT3 axis cascade. Research (Wash D C) 2025; 8: 901. [PMID: 41035818 DOI: 10.34133/research.0901]

[14] Xie R, Li T, Gao H, Xie C, Yuan H, et al. Single-cell transcriptional profiling reveals cellular senescence and inflammatory persistence as key features of type 1 diabetes partial remission. Diabetes Obes Metab 2025; 27(7): 3653-75. [PMID: 40183401 DOI: 10.1111/dom.16384]

[15] Zhao Z, Cai H, Nie W, Wang X, Zhao Z, et al. Ectopic expression of GDF15 in cancer-associated fibroblasts enhances melanoma immunosuppression via the GFRAL/RET cascade. J Immunother Cancer 2025; 13(6): e011036. [PMID: 40555562 DOI: 10.1136/jitc-2024-011036]

[16] Wang S, Greenbaum J, Qiu C, Swerdlow RH, Haeri M, et al. Gene interactions analysis of brain spatial transcriptome for Alzheimer’s disease. Genes Dis 2024; 11(6): 101337. [PMID: 39281834 DOI: 10.1016/j.gendis.2024.101337]

[17] Yadav MK, Maharana J, Yadav R, Saha S, Sarma P, et al. Molecular basis of anaphylatoxin binding, activation, and signaling bias at complement receptors. Cell 2023; 186(22): 4956-73. [PMID: 37852260 DOI: 10.1016/j.cell.2023.09.020]

[18] Young SG, Fong LG, Beigneux AP, Allan CM, He C, et al. GPIHBP1 and lipoprotein lipase, partners in plasma triglyceride metabolism. Cell Metab 2019; 30(1): 51-65. [PMID: 31269429 DOI: 10.1016/j.cmet.2019.05.023]

[19] Li Y, Lu Y, Lin SH, Li N, Han Y, et al. Insulin signaling establishes a developmental trajectory of adipose regulatory T cells. Nat Immunol 2021; 22(9): 1175-85. [PMID: 34429546 DOI: 10.1038/s41590-021-01010-3]

[20] Tadokoro T, Murata S, Kato M, Ueno Y, Tsuchida T, et al. Human iPSC-liver organoid transplantation reduces fibrosis through immunomodulation. Sci Transl Med 2024; 16(757): eadg0338. [PMID: 39047116 DOI: 10.1126/scitranslmed.adg0338]

[21] Liu Z, Chen C, Zhang Y, Ji F, Liu H, et al. Legumain in situ engineering promotes efferocytosis of CAR macrophage to treat cardiac fibrosis. Adv Mater 2025; 37(27): e2417831. [PMID: 40223483 DOI: 10.1002/adma.202417831]

[22] Lei S, Chen C, Han F, Deng J, Huang D, et al. AMER1 deficiency promotes the distant metastasis of colorectal cancer by inhibiting SLC7A11- and FTL-mediated ferroptosis. Cell Rep 2023; 42(9): 113110. [PMID: 37682704 DOI: 10.1016/j.celrep.2023.113110]

[23] Straeten F, Zhu J, Börsch AL, Zhang B, Li K, et al. Integrated single-cell transcriptomics of cerebrospinal fluid cells in treatment-naïve multiple sclerosis. J Neuroinflammation 2022; 19(1): 306. [PMID: 36536441 DOI: 10.1186/s12974-022-02667-9]

[24] Falcão AM, van Bruggen D, Marques S, Meijer M, Jäkel S, et al. Disease-specific oligodendrocyte lineage cells arise in multiple sclerosis. Nat Med 2018; 24(12): 1837-44. [PMID: 30420755 DOI: 10.1038/s41591-018-0236-y]

[25] Böttcher C, van der Poel M, Fernández-Zapata C, Schlickeiser S, Leman JKH, et al. Single-cell mass cytometry reveals complex myeloid cell composition in active lesions of progressive multiple sclerosis. Acta Neuropathol Commun 2020; 8(1): 136. [PMID: 32811567 DOI: 10.1186/s40478-020-01010-8]

[26] Shahriar S, Biswas S, Zhao K, Akcan U, Tuohy MC, et al. VEGF-A-mediated venous endothelial cell proliferation results in neoangiogenesis during neuroinflammation. Nat Neurosci 2024; 27(10): 1904-17. [PMID: 39256571 DOI: 10.1038/s41593-024-01746-9]

[27] Fagiani F, Pedrini E, Taverna S, Brambilla E, Murtaj V, et al. A glia-enriched stem cell 3D model of the human brain mimics the glial-immune neurodegenerative phenotypes of multiple sclerosis. Cell Rep Med 2024; 5(8): 101680. [PMID: 39121861 DOI: 10.1016/j.xcrm.2024.101680]

[28] Jäkel S, Agirre E, Mendanha Falcao A, van Bruggen D, Lee KW, et al. Altered human oligodendrocyte heterogeneity in multiple sclerosis. Nature 2019; 566(7745): 543-47. [PMID: 30747918 DOI: 10.1038/s41586-019-0903-2]

[29] Yu H, Bai S, Hao Y, Guan Y. Fatty acids role in multiple sclerosis as “metabokines”. J Neuroinflammation 2022; 19: 157. [PMID: 35715809 DOI: 10.1186/s12974-022-02502-1]

[30] Lu YB, Chen CX, Huang J, Tian YX, Xie X, et al. Nicotinamide phosphoribosyltransferase secreted from microglia via exosome during ischemic injury. J Neurochem 2019; 150(6): 723-37. [PMID: 31269239 DOI: 10.1111/jnc.14811]

[31] Chen F, Weng Z, Xia Q, Cao C, Leak RK, et al. Intracerebroventricular delivery of recombinant NAMPT deters inflammation and protects against cerebral ischemia. Transl Stroke Res 2019; 10(6): 719-28. [PMID: 30820847 DOI: 10.1007/s12975-019-00692-0]

[32] Jing Z, Xing J, Chen X, Stetler RA, Weng Z, et al. Neuronal NAMPT is released after cerebral ischemia and protects against white matter injury. J Cereb Blood Flow Metab 2014; 34(10): 1613-21. [PMID: 25005877 DOI: 10.1038/jcbfm.2014.119]

[33] Balzano N, Di Napoli R, Fraenza F, Di Giulio Cesare D, Moreggia O, et al. Lymphopenia associated with sphingosine 1-phosphate receptor modulators (S1PRMs) in multiple sclerosis: analysis of European pharmacovigilance data. Pharmacol Rep 2025; 77(3): 775-88. [PMID: 40199814 DOI: 10.1007/s43440-025-00725-6]

[34] Renoux F, Stellato M, Haftmann C, Vogetseder A, Huang R, et al. The AP1 transcription factor Fosl2 promotes systemic autoimmunity and inflammation by repressing Treg development. Cell Rep 2020; 31(3): 107826. [PMID: 32610127 DOI: 10.1016/j.celrep.2020.107826]

[35] Wu Y, Yang J, Chen M, Chen X, Cao S. Synovial CXCL3⁺ FOSL2⁺ macrophages mediate inflammation via FOSL2/AP-1 in rheumatoid arthritis: a single-cell transcriptome analysis. Int J Mol Sci 2025; 26(19): 9718. [PMID: 41096984 DOI: 10.3390/ijms26199718]

[36] Yuan Z, Chen R, Fan R, Yang Z, Zhu Q, et al. FOSL2⁺ macrophages drive pro-inflammatory phenotype via miR-92a-3p/FOSL2/NF-κB axis to mediate endothelial cell injury in aortic dissection. Life Sci 2026; 388: 124174. [PMID: 41453656 DOI: 10.1016/j.lfs.2025.124174]

[37] Sun X, Dai G, Yu L, Hu Q, Chen J, et al. miR-143-3p inhibits the proliferation, migration and invasion in osteosarcoma by targeting FOSL2. Sci Rep 2018; 8(1): 606. [PMID: 29330462 DOI: 10.1038/s41598-017-18739-3]

[38] He J, Mai J, Li Y, Chen L, Xu H, et al. miR-597 inhibits breast cancer cell proliferation, migration and invasion through FOSL2. Oncol Rep 2017; 37(5): 2672-78. [PMID: 28393251 DOI: 10.3892/or.2017.5558]

[39] Liu W, Xia K, Huang X, Wei Z, Wei Z, et al. IRF2BPL inhibits proliferation, migration and invasion of osteosarcoma cells by inhibiting FOSL2-mediated PI3K/AKT pathway activation. Cell Signal 2025; 135: 112068. [DOI: 10.1016/j.cellsig.2025.112068]

[40] Gao P, Yuan S, Wang Y, Wang Y, Li X, et al. Corydalis decumbens and tetrahydropalmatrubin inhibit macrophages inflammation to relieve rheumatoid arthritis by targeting Fosl2. J Ethnopharmacol 2025; 341: 119348. [PMID: 39805480 DOI: 10.1016/j.jep.2025.119348]

[41] Du J, An Z. SPI1 affects Aβ_1-42-induced microglia-mediated neuroinflammation by transcriptionally regulating FOSL2 expression. J Neuroimmunol 2025; 406: 578650. [PMID: 40449341 DOI: 10.1016/j.jneuroim.2025.578650]